KYNB

Business Context and Reporting Period

Kyntra Bio, Inc. (formerly FibroGen, Inc.) filed its Quarterly Report on Form 10-Q for the period ended March 31, 2026. The company rebranded in January 2026 to reflect a strategic transformation focusing on oncology and rare disease assets. Key developments include the divestiture of its China operations to AstraZeneca in August 2025 (classified as discontinued operations) and the advancement of its lead oncology candidate, FG-3246, into a Phase 2 monotherapy study for metastatic castration-resistant prostate cancer (mCRPC).

Key Financial Metrics

Note: Q1 2025 Net Income included $21.4 million from discontinued operations (China divestiture). Q1 2026 Net Loss includes a $0.1 million loss from discontinued operations.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 36% year-over-year, driven by a 35% increase in drug product revenue ($3.5 million vs. $2.6 million). This was primarily due to $5.7 million in revenue recognized under the Astellas Europe Agreement, partially offset by a $2.2 million revenue reduction under the Astellas Japan Agreement due to variable consideration adjustments.
• Cost of Goods Sold (COGS): COGS surged 1,529% to $4.1 million, directly correlating with the increase in drug product revenue recognized from Astellas.
• Operating Expenses: Total operating costs remained relatively flat ($17.6 million vs. $17.7 million). Research and Development (R&D) expenses decreased 18% to $7.6 million due to headcount reductions, while Selling, General, and Administrative (SG&A) expenses decreased 28% to $5.9 million.
• Liquidity: Cash and cash equivalents decreased by approximately $10.9 million quarter-over-quarter, primarily due to cash used in operating activities.

Outlook, Risks, and Contingencies

• Nasdaq Compliance: The company received a notification in April 2026 that it no longer complies with the Nasdaq Global Select Market listing requirement for total assets and revenue due to the classification of China operations as discontinued. The company intends to submit a compliance plan or consider transferring to the Nasdaq Capital Market.
• Debt Obligations: The company holds a Revenue Interest Financing Agreement (RIFA) with NovaQuest, carrying a liability of $68.3 million. The effective interest rate is approximately 15.2%, with potential balloon payments due in 2029 and 2031 if revenue targets are not met.
• Subsequent Event: In April 2026, the company's subsidiary, FibroGen Europe Oy, voluntarily submitted for bankruptcy in Finland regarding product development obligations to TEKES (approx. $19.3 million in principal and accrued interest). The company expects eventual debt relief but notes the timing and outcome are uncertain.
• Legal Proceedings: The company settled a securities class action in Q1 2025 (fully covered by insurance) and settled an SEC investigation regarding roxadustat cardiovascular data in May 2025 for a $1.25 million civil penalty.

Investor Verification Checklist

• Nasdaq Status: Verify the status of the compliance plan submitted to Nasdaq and the likelihood of a transfer to the Capital Market or potential delisting.
• RIFA Terms: Review the specific triggers for the NovaQuest RIFA balloon payments and the company's cash runway relative to these obligations.
• FG-3246 Progress: Monitor enrollment and interim data for the Phase 2 monotherapy study in mCRPC, with results expected in Q4 2026.
• Roxadustat MDS Program: Track the finalization of the Phase 3 trial protocol for roxadustat in lower-risk myelodysplastic syndromes (MDS) following FDA feedback.
• Bankruptcy Outcome: Assess the financial impact of the FibroGen Europe Oy bankruptcy proceedings on the consolidated balance sheet.